On Oct. 26, 2021, Moderna announced that Swissmedic had authorized a booster dose of Spikevax, the Company’s vaccine against COVID-19, at the 50 ﾵg dose level in particularly vulnerable individuals 12 years of age and older, at least six months after completion of the primary series.

Swissmedic also approved a third dose of Spikevax at the 100 ﾵg dose level for people with a weakened immune system at least 28 days after the second dose.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past six years.